GlassScriptPhysician profile
Robert J Rutkowski
NPI 1447349972
$6,143.86
in general payments reported to CMS, 2019-2025
43 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $1,620 · 2021: $1,522 · 2022: $1,079 · 2023: $493 · 2024: $562 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.65 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $456.67 | 2019-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $450.85 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $426.76 | 2019-2020 | |
| Amgen INC. | $364.09 | 2019-2020 | |
| Pfizer INC. | $310.10 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $231.08 | 2019-2022 | Xyosted, Tlando |
| Amarin Pharma, INC. | $194.76 | 2020-2021 | |
| Inspire Medical Systems, INC. | $193.07 | 2022-2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $183.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $177.11 | 2019-2021 | |
| Eisai INC. | $170.22 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $163.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.23 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.40 | 2022-2024 | Xifaxan, Trulance |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $143.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $141.56 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.33 | 2021 | |
| Novo Nordisk INC | $127.98 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.65 | 2020-2021 | |
| Astellas Pharma US INC | $99.70 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $96.27 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $95.78 | 2020-2021 | |
| Antares Pharma, INC. | $88.46 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Vivus LLC | $81.56 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $71.98 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $70.68 | 2024-2025 | Azmiro, Horizant, Edarbyclor |
| Exact Sciences Corporation | $62.70 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Halozyme INC | $62.20 | 2023 | |
| Corium, LLC | $47.07 | 2023 | Azstarys |
| Clarus Therapeutics INC. | $45.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.75 | 2024 | Camzyos, Eliquis |
| Arbor Pharmaceuticals, INC. | $43.79 | 2019-2022 | |
| Shire North American Group INC | $41.60 | 2019 | |
| Boston Scientific Corporation | $41.52 | 2022 | |
| Genentech USA, INC. | $38.61 | 2019-2021 | |
| Lundbeck LLC | $37.04 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $35.68 | 2019-2022 | |
| Harmony Biosciences LLC | $32.14 | 2023 | Wakix |
| Bausch Health US, LLC | $16.79 | 2019 | |
| Verity Pharmaceuticals INC. | $15.25 | 2025 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rutkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.